TY -的T1 - <一口> 18 < /一口>氟脱氧葡萄糖正电子发射断层扫描脊髓代谢亢进肿瘤区别于炎症性脊髓病(P06.142) JF -神经学乔-神经病学SP - P06.142 LP - P06.142六世- 80 - 7补充AU - Eoin弗拉纳根AU -克里斯托弗·亨特AU - Val劳盟Jayawant Mandrekar盟-肖恩首页Pittock盟Brian O’neill盟-马克Keegan Y1 - 2013/02/12 UR - //www.ez-admanager.com/content/80/7_Supplement/P06.142.abstract N2 -目的:探讨脊髓的使用18 f-fluorodeoxyglucose正电子发射断层扫描(正)患者的脊髓病的不确定的病因。背景:脊髓摄影是一个可能的工具评估治疗脊髓炎的不确定的病因。我们假设正代谢亢进可能从炎症病因鉴别肿瘤脊髓炎。设计/方法:我们回顾性梅奥诊所患者从1996 - 2011年脊髓病由于脊髓髓内病变诊断正被执行。压患者骨髓脊髓炎,辐射脊髓病或慢性脊髓炎与已知的病因被排除在外。51例患者包括(53%的女性)的平均年龄60年(20 - 82年)。患者肿瘤或炎症病因non-neurosarcoid一分为二。Neurosarcoid脊髓炎是先天摄影hypermetabolic因此分别进行了分析。两个放射科医生独立评估摄影在代谢亢进和最大标准摄入值(SUVmax)盲底层脊髓病病因。结果:脊髓与肿瘤代谢亢进是更常见的脊髓病(17/21;81%)比炎症性脊髓病(6/24;25%)(术中,0.001)。 Further, median SUVmax was greater in neoplastic than inflammatory causes of myelopathy (3.3 g/ml vs 1.9 g/ml; p<0.001). Agreement between radiologist's assessments was excellent (Κ=0.88). Inflammatory myelopathic diagnoses (n=24) were: paraneoplastic 13, autoimmune/other 5, inflammatory demyelinating 4, transverse myelitis 2. Neoplastic diagnoses (n=21) were: intramedullary metastases 12; intramedullary lymphoma/leukemia 7; and primary intramedullary neoplasm 2. Six patients had neurosarcoid myelopathy. FDG-PET hypermetabolism was seen in three patients with neurosarcoid myelopathy (median SUVmax 2.6 g/ml; range, 1.8-12.2).CONCLUSIONS: Spinal cord FDG-PET hypermetabolism is more common in neoplastic myelopathies than in inflammatory myelopathies and may be useful in evaluating myelopathy of uncertain etiology to discriminate neoplastic from inflammatory etiologies.Disclosure: Dr. Flanagan has nothing to disclose. Dr. Hunt has nothing to disclose. Dr. Lowe received personal compensation for consulting from Bayer Pharmaceuticals. Dr. Lowe received research grants from GE Health Care, Siemens Molecular Imaging, and AVID Radiopharmaceuticals, Inc. Dr. Mandrekar has nothing to disclose. Dr. Pittock and Mayo Clinic have a financial interest in the technology entitled "Neuromyelitis Optica Autoantibodies as a Marker for Neoplasia." This technology has been licensed to a commercial entity but no royalties have been received. Dr Sean Pittock has received research support from Alexion Pharmaceuticals, Inc. Dr. O'Neill has received personal compensation for activities with McGraw-Hill. Dr. O'Neill has received personal compensation in an editorial capacity for Neuro-oncology. Dr. O'Neill has received compensation for serving on the Board of CellDex Data Safety Monitoring Board. Dr. O'Neill holds stock and/or stock options in Johnson & Johnson. Dr. Keegan has received personal compensation for activities with BIONEST Partners and Glaxo-Smith-Klein as a consultant. Dr. Keegan received compensation as a section editor for Neurology. Dr. Keegan has received research support from Caridian BCT.Thursday, March 21 2013, 7:30 am-12:00 pm ER -